213 related articles for article (PubMed ID: 24078283)
1. Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation.
Rodrigues L; Matafome P; Crisóstomo J; Santos-Silva D; Sena C; Pereira P; Seiça R
J Physiol Biochem; 2014 Mar; 70(1):173-84. PubMed ID: 24078283
[TBL] [Abstract][Full Text] [Related]
2. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
3. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
Bierhaus A; Ritz E; Nawroth PP
Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of polysaccharides from Liriope spicata var. prolifera on diabetic nephropathy in rats.
Xiao ZQ; Wang YL; Yue YD; Zhang YT; Chen CP; Wan LS; Deng B; Liu ZX; Chen JC
Int J Biol Macromol; 2013 Oct; 61():114-20. PubMed ID: 23831538
[TBL] [Abstract][Full Text] [Related]
5. Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia disease in Wistar normal rats.
Crisóstomo J; Matafome P; Santos-Silva D; Rodrigues L; Sena CM; Pereira P; Seiça R
Nutr Metab Cardiovasc Dis; 2013 Dec; 23(12):1223-30. PubMed ID: 23642929
[TBL] [Abstract][Full Text] [Related]
6. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Wihler C; Schäfer S; Schmid K; Deemer EK; Münch G; Bleich M; Busch AE; Dingermann T; Somoza V; Baynes JW; Huber J
Diabetologia; 2005 Aug; 48(8):1645-53. PubMed ID: 16010524
[TBL] [Abstract][Full Text] [Related]
7. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
Forbes JM; Thallas V; Thomas MC; Founds HW; Burns WC; Jerums G; Cooper ME
FASEB J; 2003 Sep; 17(12):1762-4. PubMed ID: 12958202
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of diabetic nephropathy: a radical approach.
Salahudeen AK; Kanji V; Reckelhoff JF; Schmidt AM
Nephrol Dial Transplant; 1997 Apr; 12(4):664-8. PubMed ID: 9140991
[No Abstract] [Full Text] [Related]
9. Novel inhibitors of glycation and AGE formation.
Rahbar S
Cell Biochem Biophys; 2007; 48(2-3):147-57. PubMed ID: 17709884
[TBL] [Abstract][Full Text] [Related]
10. Diabetic nephropathy and advanced glycation end products.
Menè P; Festuccia F; Polci R; Pugliese F; Cinotti GA
Contrib Nephrol; 2001; (131):22-32. PubMed ID: 11125560
[No Abstract] [Full Text] [Related]
11. Methylglyoxal promotes oxidative stress and endothelial dysfunction.
Sena CM; Matafome P; Crisóstomo J; Rodrigues L; Fernandes R; Pereira P; Seiça RM
Pharmacol Res; 2012 May; 65(5):497-506. PubMed ID: 22425979
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products, oxidative stress and diabetic nephropathy.
Yamagishi S; Matsui T
Oxid Med Cell Longev; 2010; 3(2):101-8. PubMed ID: 20716934
[TBL] [Abstract][Full Text] [Related]
13. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Nangaku M; Miyata T; Sada T; Mizuno M; Inagi R; Ueda Y; Ishikawa N; Yuzawa H; Koike H; van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
[TBL] [Abstract][Full Text] [Related]
14. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.
Tanji N; Markowitz GS; Fu C; Kislinger T; Taguchi A; Pischetsrieder M; Stern D; Schmidt AM; D'Agati VD
J Am Soc Nephrol; 2000 Sep; 11(9):1656-1666. PubMed ID: 10966490
[TBL] [Abstract][Full Text] [Related]
15. Role of Calbindin-D28k in Diabetes-Associated Advanced Glycation End-Products-Induced Renal Proximal Tubule Cell Injury.
Huang KH; Guan SS; Lin WH; Wu CT; Sheu ML; Chiang CK; Liu SH
Cells; 2019 Jun; 8(7):. PubMed ID: 31262060
[TBL] [Abstract][Full Text] [Related]
16. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia in the diabetic kidney is independent of advanced glycation end-products.
Nordquist L; Liss P; Fasching A; Hansell P; Palm F
Adv Exp Med Biol; 2013; 765():185-193. PubMed ID: 22879032
[TBL] [Abstract][Full Text] [Related]
18. Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?
Zhuang A; Forbes JM
Glycoconj J; 2016 Aug; 33(4):645-52. PubMed ID: 27270766
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products and the progressive course of renal disease.
Heidland A; Sebekova K; Schinzel R
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S100-6. PubMed ID: 11576932
[TBL] [Abstract][Full Text] [Related]
20. DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice.
Sotokawauchi A; Matsui T; Higashimoto Y; Nishino Y; Koga Y; Yagi M; Yamagishi SI
Diab Vasc Dis Res; 2021; 18(1):1479164121990533. PubMed ID: 33535822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
